Odanacatib: Location and timing are everything
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Antiresorptive drugs have become the mainstay for the prevention and treatment of osteoporosis. Members of this class include estrogen, the selective estrogen receptor modulator raloxifene, four bisphosphonates (alendronate, risedronate, ibandronate, and zoledronic acid), and the receptor activator of NF-κB ligand (RANKL) inhibitor denosumab.1 In contrast to this plethora of antiresorptive compounds, the sole formation-stimulating agent currently available is teriparatide.1 Thus, although there is clearly a clinical need for the development of additional formation-stimulating drugs, it remains an open question as to whether the osteoporosis market has room for yet another antiresorptive compound. It is in this context that location and timing become critical for a new antiresorptive drug. In terms of location, does the new drug offer advantages with regards to the compartment-specific (ie, trabecular, endocortical, periosteal) effects of the drug? And in terms of timing, is the new drug coming to market when there are concerns (real or perceived) regarding the efficacy or safety of currently available alternatives? Given the costs of bringing a new drug to market, these are high-stakes questions for another antiresorptive drug for osteoporosis. In the current issue of JBMR, two articles from Merck Research Laboratories2, 3 collectively address the question of location for the antiresorptive compound odanacatib (ODN), which is just entering this high-stakes arena and is currently in phase 3 trials. ODN is a selective and reversible inhibitor of cathepsin K (CatK), which is a lysosomal cysteine proteinase that is highly expressed in osteoclasts and is critical for bone resorption.4 Both articles are based on analyses of a carefully conducted primate study in which ovariectomized Rhesus monkeys were treated with either vehicle, ODN 6 mg/kg/d, or ODN 30 mg/kg/d for 21 months and compared with intact animals; Masarachia and colleagues2 report results at the lumbar spine and Cusick and colleagues3 present the hip data. The spine data are not particularly striking and barely distinguish ODN from other antiresorptive agents.2 As might be expected with any potent antiresorptive drug, ODN at both doses prevented bone loss at the spine and maintained bone mass at a level comparable to intact animals. This was accompanied by a suppression of bone resorption markers (urinary N-telopeptide of type I collagen [NTx] by 75% to 90% and serum C-telopeptide of type I collagen [CTx] by 40% to 55%) versus vehicle-treated ovariectomized monkeys. Serum bone formation markers also decreased in the ODN-treated groups compared with vehicle-treated ovariectomized animals (bone-specific alkaline phosphatase [BSAP] by 30% to 35% and amino-terminal propeptide of type I procollagen [P1NP] by 60% to 70%), and consistent with these changes, histologically measured bone formation rates (BFRs) in trabecular bone at the iliac crest and lumbar vertebrae decreased by comparable amounts. It was in the detailed analysis of osteoclast numbers and morphology and the compartment-specific bone formation data at the hip that things got a lot more interesting.2, 3 First, despite the marked reduction in bone resorption, ODN did not reduce but rather tended to increase (by ∼twofold) osteoclast numbers in trabecular bone at both the spine and hip. Moreover, in contrast to previous data with the bisphosphonate alendronate, where there was an increase in apoptotic and giant, hypermultinucleated osteoclasts,5 the osteoclasts in the ODN-treated animals appeared relatively normal with the exception of an increase in intracellular vesicles that stained darkly with toluidine blue. These findings also contrast sharply with denosumab therapy, which has been shown to lead to a marked reduction in osteoclasts on bone surfaces.6 The second distinguishing feature of ODN versus other antiresorptive agents came from the analysis of trabecular, intracortical, endocortical, and periosteal BFRs at the hip.3 Consistent with the findings at the iliac crest and spine, ODN reduced BFR in trabecular bone at the hip. ODN similarly reduced intracortical BFR but interestingly, it had no effect on endocortical BFR. Most surprising, however, were consistent 3.5- and 6-fold increases in periosteal BFRs at the femur neck and proximal femur, respectively. This, in turn, resulted in a 21% (p = 0.08) and 19% (p < 0.05) increase in cortical thickness at the femur neck and proximal femur, respectively. Of note, a similar increase in periosteal BFR at the mid-femur has previously been reported in ovariectomized cynomolgus monkeys treated with another CatK inhibitor, balicatib, for 18 months.7 To summarize, based on the primate data2, 3 and consistent with a previous phase 2 study in postmenopausal women,8 ODN appears to be a self-respecting antiresorptive agent. But, to break into the saturated antiresorptive market, it needs to be "more." This more, at least in terms of location, may hinge
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shane, E., Burr, D., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., Dempster, D. W., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1998 · Cited by 2,147
Khosla, S., Burr, D., Cauley, J., Dempster, D. W., Ebeling, P. R., Felsenberg, D., Gagel, R. F., Gilsanz, V., Guise, T., Koka, S., et al. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0707onj · Cited by 1,650 · cited 1×
“This will depend on whether some of the well-publicized, but extremely rare, complications of osteonecrosis of the jaw((15)) and atypical subtrochanteric fractures((16)) associated with bisphosphonates and likely also”
BackgroundSelf-citationBidirectional ephrinB2-EphB4 signaling controls bone homeostasis
Zhao, C., Irie, N., Takada, Y., Shimoda, K., Miyamoto, T., Nishiwaki, T., Suda, T., & Matsuo, K. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.05.012 · Cited by 777
Giant Osteoclast Formation and Long-Term Oral Bisphosphonate Therapy
Weinstein, R. S., Roberson, P. K., & Manolagas, S. C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0802633 · Cited by 391
Cited by
Targeting cellular senescence prevents age-related bone loss in mice
Farr, J. N., Xu, M., Weivoda, M. M., Monroe, D. G., Fraser, D. G., Onken, J. L., Negley, B. A., Sfeir, J. G., Ogrodnik, M. B., Hachfeld, C. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4385 · Cited by 1,182
Self-citationOsteoporosis treatment: recent developments and ongoing challenges
Khosla, S., & Hofbauer, L. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30188-2 · Cited by 1,019
Self-citationThe role of cellular senescence in ageing and endocrine disease
Khosla, S., Farr, J. N., Tchkonia, T., & Kirkland, J. L. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0335-y · Cited by 523
Self-citationRegulation of Bone Metabolism by Sex Steroids
Khosla, S., & Monroe, D. G. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031211 · Cited by 323
Self-citationFarr, J. N., & Khosla, S. (2019) · Bone · doi:10.1016/j.bone.2019.01.015 · Cited by 263
“Indeed, all currently approved drugs for osteoporosis either inhibit bone resorption with a marked, coupled reduction in bone formation (bisphosphonates, denosumab, estrogen) [101] or transiently stimulate bone formation with a coupled increase in bone resorption (PTH) [101].”
BackgroundSelf-citation
Metadata
- Authors
- Khosla, S.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-02-21
- Volume
- 27
- Issue
- 3
- Pages
- 506-508
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W1995262934
- Cited by
- 37
- References
- 4
- FWCI
- 2.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.